Mammoth Biosciences has Developed a Fast, Efficient, and Automated Turnkey Workstation Diagnostics Approach for COVID-19

Mammoth Biosciences is a San Francisco based company that specializes in CRISPR technology for Covid-19 testing, and has developed a fast, efficient, and automated turnkey workstation diagnostics approach. 

Trevor Martin, Co-Founder and CEO

Mammoth Biosciences is a San Francisco-based company that uses CRISPR technology to detect the presence of Covid-19. Founded by a Nobel Prize winner, the company is “harnessing the diversity of nature to power the next generation of CRISPR products.” Using a proprietary discovery platform, Mammoth Biosciences can identify novel Cas proteins. Their Covid-19 testing approach is fast, automated, and efficient.

Based around a turkey workstation, Mammoth’s CRISPR-based SARS-CoV-2 molecular assay uses automated liquid handling equipment. This system can handle 1,500 tests in eight hours, and very little hands-on labor is required from lab technicians. 

All the way back in January of 2020, Mammoth Bioscience raised $45 million in funding for CRISPR diagnostics and immediately started adapting its technology for Covid-19 testing. At this point, the company had received total funding of over $70 million. In July of 2020, Mammoth was one of seven companies that were awarded almost $250 in combined contracts from the NIH after its RADx initiative. In August of 2020, Mammoth Biosciences signed an exclusive deal to license a new class of CRISPR proteins. In October of 2020, the company partnered with MilliporeSigma and Hamilton company in order to commercialize its DETECTR BOOST™ SARS-CoV-2 assay reagent kits and scale up its testing infrastructure. 

Learn More:


Comments are closed.

Share This